# Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results
Canonical URL: https://biopharmsignal.com/news/KURA/kura-oncology-to-report-fourth-quarter-and-full-year-2025-financial-results
Ticker: KURA
Company: Kura Oncology
Source: Kura Oncology
Published: 2026-02-26 12:30 EST
Original Source URL: https://ir.kuraoncology.com
## Summary

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, March

## Article Body
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, March
## Recent Company News
- 2026-06-03 10:53 EST — [Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy](https://biopharmsignal.com/news/KURA/kura-oncology-highlights-darlifarnib-s-potential-as-a-foundational-combination-platform-for-kras-mutant-cancers-and-outlines-development-strategy) — Source: Kura Oncology
- 2026-06-02 12:32 EST — [Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML](https://biopharmsignal.com/news/KURA/kura-oncology-and-kyowa-kirin-announce-publication-in-blood-of-ziftomenib-plus-venetoclax-azacitidine-combination-in-patients-with-r-r-npm1-m-aml) — Source: Kura Oncology
- 2026-05-26 10:02 EST — [Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors](https://biopharmsignal.com/news/KURA/kura-oncology-reports-strong-clinical-activity-and-safety-with-darlifarnib-adagrasib-in-kras-g12c-mutated-solid-tumors) — Source: Kura Oncology
- 2026-05-19 20:02 EST — [Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit](https://biopharmsignal.com/news/KURA/kura-oncology-to-present-at-td-cowen-7th-annual-oncology-innovation-summit) — Source: Kura Oncology
- 2026-05-12 20:02 EST — [Kura Oncology Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/KURA/kura-oncology-reports-first-quarter-2026-financial-results) — Source: Kura Oncology
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)